	US 11,911,468 B2
	Compositions and methods of treating sarcoma lung metastasis
Alex Yee-Chen Huang, Solon, OH (US); and Jay T. Myers, Shaker Heights, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on May 4, 2021, as Appl. No. 17/307,709.
Application 17/307,709 is a continuation of application No. 16/018,741, filed on Jun. 26, 2018, granted, now 10,994,009.
Claims priority of provisional application 62/525,080, filed on Jun. 26, 2017.
Prior Publication US 2021/0393774 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 38/17 (2006.01); A61K 31/663 (2006.01); C07K 16/28 (2006.01); A61K 41/17 (2020.01); A61P 35/04 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 31/663 (2013.01); A61K 38/1774 (2013.01); A61K 41/17 (2020.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2842 (2013.01); A61K 2039/505 (2013.01); A61K 2039/543 (2013.01); A61K 2039/544 (2013.01); A61K 2039/585 (2013.01); A61K 2300/00 (2013.01); C07K 2317/76 (2013.01)]

10 Claims

1. A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/α4β1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing α4β1, wherein the agent is an inhibitory anti-VCAM peptide consisting of the amino acid sequence of SEQ ID NO:1.